PREGABALIN

Pregabalin modulates voltage‑gated calcium channels in the CNS, reducing the release of excitatory neurotransmitters. It is used in neuropathic pain, fibromyalgia, and partial seizures. Benefits include pain relief and improved sleep. Side effects include dizziness, somnolence, peripheral edema, weight gain, blurred vision, and possible mood or behavioral changes.

SKU: c566a2ce3dda Category: Tag:

Product Description


Mechanism of Action

PREGABALIN (ID 27222) exhibits a complex, multi‑pathway biochemical activity profile influencing enzymatic cascades, receptor‑mediated signalling networks, mitochondrial respiration, oxidative‑stress balance, intracellular ion regulation, membrane‑potential stability and transcription‑factor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membrane‑embedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, second‑messenger systems (Ca²⁺, IP₃, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stress‑response thresholds.

Depending on dosing, PREGABALIN can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multi‑axis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptor–ligand interaction analysis and affinity modelling
  • Enzyme‑kinetic profiling and catalytic‑pathway reconstruction
  • Mitochondrial‑bioenergetics assays and oxidative‑stress evaluation
  • Multi‑omics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structure–activity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic dose–response simulations

Side Effects and Risks

Potential laboratory‑observed risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electron‑transport complexes
  • Ion‑channel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor cross‑talk or inhibition
  • Cytoskeletal destabilisation and membrane‑integrity compromise
  • Dose‑dependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF‑κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Datasheet


Molecular Formula

C8H17NO2

Molecular Weight

159.23 g/mol

CAS Number

148553-50-8

Storage Condition

Store at 25 °C (77 °F); excursions permitted to 15 to 30 °C (59 to 86 °F).

Solubility

Freely soluble

Purity

Purity information is available upon request (COA).

Synonym

Pregabalin; 148553-50-8; Lyrica; (S)-3-(Aminomethyl)-5-methylhexanoic acid; 3-isobutyl GABA

IUPAC/Chemical Name

(3S)-3-(aminomethyl)-5-methylhexanoic acid

InChl Key

AYXYPKUFHZROOJ-ZETCQYMHSA-N

InChl Code

InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/5486971;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download